Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2010

View Archived Issues

French scientists claim epipodophyllotoxin derivatives with antitumor activity

Janssen presents novel TRPM8 receptor antagonists

New urocortin III fragments with antidepressant/anxiolytic activity claimed by Hungarian scientists

Sequoia Pharmaceuticals discovers NS3/NS4A protease inhibitors for HCV infections

Hetero Research Foundation presents new SGLT inhibitors

Vitae Pharmaceuticals identifies novel beta-secretase inhibitors

Studies detail PEP-005 efficacy for actinic keratoses on head and nonhead areas

Phase III trial of magnesium sulfate in acute stroke currently recruiting participants

Phase III data on Cervarix for the prevention of HPV-associated cervical cancer disclosed

Korean scientists identify new dual PPAR-alpha/gamma activator

Trillium expands immunology pipeline and enters stem cell field

Pfizer discontinues phase III trial of figitumumab in NSCLC

Ipsen grants Rhythm worldwide license for two programs in metabolic disorders

Once-daily nemonoxacin meets primary endpoints in phase II trial in diabetic foot infection

FDA accepts for review Abbott's Lupron sNDA for prostate cancer

FDA approves Watson Pharmaceuticals' twice-yearly Trelstar formulation for prostate cancer

Manhattan and Ariston Pharmaceuticals complete merger

FDA approves 5-day dosing of Eisai's Dacogen for MDS

Pfizer reports on phase III Sutent trials in advanced breast cancer

Medivir's Xerclear cold sore therapy to be launched in Sweden

FDA grants orphan drug designation to Bayer HealthCare's ciprofloxacin dry powder inhaler

Progenics to advance oral methylnaltrexone into phase IIb/III trials in OIC

CBio achieves milestone under collaboration with Novo Nordisk

Acura and King report topline data on relative abuse potential Acurox

Neoprobe reports successful meeting with FDA on Lymphoseek phase III results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...